Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BioNexus Gene Lab Corp (BGLC)

BioNexus signs exclusive Malaysian healthcare AI licence with RYET, payable in shares

Neutral Impact 4 of 5 product/contract Written later

On October 5, 2026, BioNexus Gene Lab Corp. agreed to an exclusive Malaysian healthcare licence to Ruanyun Edai Technology's CogniAI document-intelligence platform, with closing still pending. The company will issue a total of 560,000 common shares, about 16.0% of its outstanding shares after issuance, with no cash payment, which shareholders would bear as dilution. The filing states that BioNexus has not been awarded any government contract and that closing depends on technology acceptance, due diligence and approvals.

Key points

  • Share consideration: 410,000 shares for a stated US$3.5 million licence fee, plus 150,000 shares for 500,000 RYET ordinary shares, totaling 560,000 shares, or about 16.0% of outstanding common shares after issuance.
  • Royalty: RYET receives 10% of defined technology receipts actually collected, with no minimum royalty or annual platform fee.
  • Closing: either non-defaulting party may terminate if closing has not occurred by March 31, 2027, unless extended.
  • Government work: BioNexus has not been awarded any government contract, and any public-sector work would depend on government procurement.

The filing

CompanyBioNexus Gene Lab Corp (BGLC)
Form8-K, current report
Filed with the SECOct 7, 2026, 9:00 AM ET
Accession number0001477932-26-006075

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.